Finasteride Sexual Side Effects Grow With Time, Data Show

The sexual risks of finasteride grow the longer men stay on the drug, according to new research that recasts one of the most widely used hair loss treatments. Finasteride sexual side effects were once described in clinical trials as uncommon and reversible, but a propensity-matched cohort study presented at the American Urological Association's 2026 meeting shows erectile dysfunction risk climbing with continued use. The analysis followed 5,091 men aged 18 to 45 with androgenetic alopecia who were prescribed finasteride 1 mg, matching each of them to a control patient of similar age, body mass index and race, along with other health conditions including depression and anxiety.

The pattern of finasteride sexual side effects took time to emerge. At the six-month mark, erectile dysfunction risk looked almost identical between the two groups, with a risk ratio of 1.32 that fell short of statistical significance. By the one-year mark, the picture had changed: 1.61 percent of finasteride users had a new erectile dysfunction diagnosis compared with 0.96 percent of controls, a risk ratio of 1.67. Three years into treatment, the gap persisted, with 3.73 percent of users affected versus 2.36 percent of controls, a risk ratio of 1.58. A separate sensitivity analysis that compared finasteride users against men taking oral minoxidil reached the same conclusion, finding a risk ratio of 2.19 for erectile dysfunction drug prescriptions at the three-year point. Taken together, the data translate to roughly a one in 27 chance of new-onset erectile dysfunction over the full follow-up period.

Why short trials missed the signal

Finasteride works by blocking the enzyme that converts testosterone into dihydrotestosterone, the hormone driving both hair follicle shrinkage and prostate growth. It is sold as Propecia at the low dose used for hair loss and as Proscar at a higher dose for enlarged prostate. That shared mechanism explains the study's most useful finding about finasteride sexual side effects: the erectile dysfunction signal is time-dependent, so the short clinical trials that regulators relied on could not have caught it. Half a year of data showed nothing meaningful, and the divergence only became clear later. The researchers who reported the findings, writing for the physician newsroom MDLinx, say the practical lesson is about informed consent. For older men treated for benign prostatic hyperplasia, the same meeting's data showed a risk ratio of 1.07, a much smaller effect, and the drug's proven benefit in preventing surgery may outweigh it. For a young man with hair loss, whose baseline risk of erectile dysfunction sits close to zero, even the modest absolute numbers deserve a frank conversation before the first prescription, documented in the medical record.

The harder question: do the effects linger?

The AUA analysis measured risk while men were taking the drug. Whether the effects stop when the drug stops is a separate question, and older research into persistent finasteride sexual side effects suggests the answer is not always reassuring. A study led by Dr. Michael Irwig at the George Washington University School of Medicine and Health Sciences, published in The Journal of Sexual Medicine, interviewed 71 otherwise healthy men aged 21 to 46 who reported new sexual problems after starting finasteride for male pattern hair loss. Low sexual desire affected 94 percent of them; more than nine in ten also reported erectile dysfunction and decreased arousal, while problems with orgasm affected roughly two in three. On average the men had taken finasteride for 28 months, and their symptoms had lasted 40 months after stopping, with sexual function measured before and after use on the Arizona Sexual Experience Scale. The study had real limits, including a post hoc design, selection bias, reliance on recalled symptoms and no hormone bloodwork. Still, Dr. Irwig said the message for prescribers was clear: "The study underscores the importance of physicians, who are treating male pattern hair loss, discussing the potential risk of persistent sexual side effects with their patients."

That concern has not faded. A cross-sectional study published this spring in the Journal of Clinical Medicine found that some patients develop persistent finasteride sexual side effects after stopping the drug, a cluster of complaints sometimes called post-finasteride syndrome. The authors note the condition's medical status remains debated, citing varied definitions, the lack of standard diagnostic criteria and limited prospective data. Even so, the review concluded that the evidence now points beyond transient side effects for a subset of patients, and it called for stronger informed-consent practices around the drug.

What men should ask before starting

The thread connecting the old and new research is timing. The new matched-cohort data suggest finasteride sexual side effects build quietly, with the signal showing up in the statistics around the first year. For anyone considering the drug, researchers say the conversation with a doctor should start with the patient's baseline risk and the goal of treatment, then turn to how much uncertainty the patient is comfortable living with. Men already taking finasteride who notice changes in desire, erections or orgasm should bring it up with their prescriber rather than quitting on their own, since stopping any hormone-altering medication deserves medical guidance. The drug remains widely used and effective for hair regrowth and prostate care; the new evidence simply puts a number on a risk that used to be discussed mostly in anecdotes.